ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.26 USD
+0.12 (0.74%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $16.27 +0.01 (0.06%) 6:38 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 221 - 240 ( 249 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Meiji-Seka Collaboration Over - Not a Big Deal
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Pimavanserin Showing Early Potential In Alzheimer''s Psychosis
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
We initiate coverage with a Buy and a $3 price target.
Provider: Roth Capital Partners, Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
A PATENTVEST IP GROWTH COMPANY - 2011 BEST AND BRIGHTEST PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC